Michigan is currently home to 2192 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Karmanos Cancer Center, Detroit, Michigan
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
Recruiting
The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk s... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
11/13/2024
Locations: University of Michigan / CS Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Acute Respiratory Distress Syndrome
Achieving Cardiovascular Health Equity in Community Mental Health: Optimizing Implementation Strategies
Recruiting
In this trial, the investigators will examine the uptake of the evidenced-based IDEAL Goals program, a heart disease risk reduction program, while testing different implementation strategies with our partners in Michigan and Maryland who serve persons with serious mental illness (SMI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cardiovascular Risk Factors, Serious Mental Illness
Intraoral Hypothermia Device for Preserving Taste During Radiation
Recruiting
Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatments to preserve or lower the decline of taste function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Head and Neck Cancer, Taste Dysfunction, Radiation Therapy
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
Recruiting
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures. Participants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an appl... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
11/13/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
Recruiting
The goal of this randomized trial is to test whether the Internet-Delivered Enhanced Assess, Acknowledge, Act (IDEA3) sexual assault resistance education intervention reduces sexual violence victimization in undergraduate women. Participants in the intervention group will be asked to attend four three-hour group sessions of a sexual assault resistance program called IDEA3 with a partner, as well as fill out a number of surveys. Participants in the control group will be asked to attend a one-hou... Read More
Gender:
ALL
Ages:
Between 17 years and 24 years
Trial Updated:
11/13/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Sexual Assault
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients with Sickle Cell Disease
Recruiting
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Sickle Cell Disease
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia
Recruiting
This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Center for Advanced Kidney Research PLC, Saint Clair Shores, Michigan
Conditions: Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Recruiting
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Non Small Cell Lung Cancer, Breast Cancer
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Recruiting
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Oral Mucositis
Study in Parkinson Disease of Exercise
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Recruiting
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Gender:
FEMALE
Ages:
Between 25 years and 100 years
Trial Updated:
11/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease